In this article, we will take a look at the Top 5 NASDAQ Stocks to Buy for Retirement. For a deeper discussion and an expanded list, please see the Top 10 NASDAQ Stocks to Buy for Retirement.
5. Kimberly-Clark Corporation (NASDAQ:KMB)
Kimberly-Clark Corporation (NASDAQ:KMB) ranks among the top NASDAQ stocks for retirement. Piper Sandler increased its price objective for Kimberly-Clark Corporation (NASDAQ:KMB) to $121 from $115 on June 17, while keeping an Overweight rating on the company’s shares. The firm highlighted that cost headwinds remain relatively manageable, aided by solid productivity gains and a recent drop in oil prices.
The updated price target is approximately 16x 2027 expected earnings per share, an increase from the previous 15x. Kimberly-Clark Corporation (NASDAQ:KMB) has expanded its June merchandising, according to the firm, and innovation is expected to pick up in the latter half of 2026.
Piper Sandler anticipated $150 million to $170 million in additional gross inflation, assuming oil at $100 per barrel, compared with $80 per barrel now. According to the firm, the upside from Kimberly Clark’s KVUE transaction will not be realized until 2028.
Kimberly-Clark Corporation (NASDAQ:KMB) is a global company focused on consumer goods, personal care products, and solutions. It operates through two segments: North America and International Personal Care.
4. Plains All American Pipeline, L.P. (NASDAQ:PAA)
Plains All American Pipeline, L.P. (NASDAQ:PAA) ranks among the top NASDAQ stocks for retirement. Following the company’s disclosure of enhanced capital expenditure for 2026, UBS restated its Buy rating and $25 price target for Plains All American Pipeline, L.P. (NASDAQ:PAA) on June 16. Plains All American Pipeline, L.P. (NASDAQ:PAA) estimates growth capital spending to increase to $400 million to $450 million net to PAA by this year, a rise from around $350 million.
The additional budget is being driven by numerous expansion plans in the company’s Permian long-haul, Canadian gathering, and Permian gathering operations. UBS observed that the global setting for oil has grown stronger since the beginning of the year, and client activity and demand have enabled the company to go forward with many high-return projects.
UBS sees increased growth capital as a plus, noting that it will propel incremental profitability at a competitive rate of return. UBS feels Plains All American Pipeline, L.P. (NASDAQ:PAA) continues to prove the bears wrong by exhibiting its organic growth potential.
Founded in 1998, Plains All American Pipeline, L.P. (NASDAQ:PAA) is an established leader in the midstream energy sector. The Texas-based company owns and operates an extensive network of pipeline transportation, terminaling, storage, and gathering assets for crude oil and natural gas liquids.
3. PepsiCo, Inc. (NASDAQ:PEP)
PepsiCo, Inc. (NASDAQ:PEP) ranks among the top NASDAQ stocks for retirement. As part of a Q2 results preview, Citi lowered its price objective for PepsiCo, Inc. (NASDAQ:PEP) to $170 from $182 and maintained a Buy rating on the stock. The firm expects PepsiCo, Inc. (NASDAQ:PEP) to report earnings per share of $2.18, lower than the average projection of $2.22.
The company is facing issues in its snacking business and is losing market share in North American beverage subcategories. However, these flaws are mitigated by a thriving multinational business.
In a similar vein, Deutsche Bank reduced its price target for PepsiCo, Inc. (NASDAQ:PEP) to $168 from $173 with a Buy rating on June 18. The firm stated that early-quarter data indicated “encouraging momentum” after the company regained positive volume growth during the first quarter. However, consumption patterns slowed in late April and May.
One of the most well-known names in the world, PepsiCo, Inc. (NASDAQ:PEP), is an American multinational company involved in the food, snack, and beverage sectors.
2. CME Group Inc. (NASDAQ:CME)
CME Group Inc. (NASDAQ:CME) ranks among the top NASDAQ stocks for retirement. On June 18, Keefe, Bruyette & Woods raised CME Group Inc. (NASDAQ:CME) to Outperform from Market Perform, retaining a $305 price objective on the company’s shares. Considering recent stock market losses, the firm highlighted an appealing risk/reward opportunity.
Keefe, Bruyette & Woods stated that the recent pressure stems from concerns about ongoing futures risk, which it believes is exaggerated for exchanges overall and for CME Group Inc. (NASDAQ:CME) in particular, given its limited retail presence and index licenses across equity products.
In addition, Piper Sandler reaffirmed its Overweight rating and $320 price target for CME Group Inc. (NASDAQ:CME) the day before in response to the company’s leadership announcement. According to CME Group Inc. (NASDAQ:CME), CEO Terry Duffy will retire in March 2027, with President and CFO Lynne Fitzpatrick taking over as CEO.
According to Piper Sandler, Fitzpatrick took over as CFO in 2023, replacing longtime CFO John Pietrowicz, and has been active on both the buy-side and sell-side over recent years.
Founded in 1898 and headquartered in Chicago, Illinois, CME Group Inc. (NASDAQ:CME) allows institutional participants to manage risk and trade futures, options, and indices across all major asset classes. The exchange offers highly regulated, cash-settled derivatives like Bitcoin and Ethereum futures and crypto-index products.
1. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company’s shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company.
Mizuho said that Novartis and Ionis Pharmaceuticals’ pelacarsen Phase 3 Lp(a) research is slated to conclude in the early second half of 2026, which might possibly assist Amgen Inc. (NASDAQ:AMGN).
Mizuho slightly increased its medium-term sales outlook for Amgen Inc. (NASDAQ:AMGN), leading to a minor price target revision. As information from the Novartis and Ionis Phase 3 Lp(a) research becomes available, likely in the first half of 2026, the firm anticipates that market focus will turn toward olpasiran. The olpasiran data is expected to be released at a later time.
Meanwhile, Mizuho noted a potential risk associated with a tax dispute resolution projected no sooner than the latter half of 2026. The firm stated that it is seeking more details on the IRS tax dispute, which, as per Amgen’s 10-Q filing, will not be resolved before the latter half of 2026.
Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Starter Stock Portfolio: 14 Safe Stocks to Buy Now and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
